制备,表征,药理动力学和性结肠炎治疗的hyperoside-loaded混合
Xingcheng Jin1, Xiaoli Xia2, Jiaying Li2
1Department of Pharmacy, the Second Affiliated Hospital, Anhui Medical University, Hefei, China.
Drug delivery and translational research
|November 13, 2023
概括
这项研究开发了超酸载荷混合小粒 (HYP-M),以增强超酸 (HYP) 的口服生物可用性和抗性结肠炎 (UC) 作用. HYP-M显著改善了HYP的表现.
科学领域:
- 药理学 药理学是指药理学的学科.
- 材料科学 材料科学 材料科学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种普遍存在的全球性疾病.
- 过氧化物 (HYP) 是一种黄类化合物,具有治疗潜力,但其口服生物利用性较低.
- 需要新的药物输送系统来提高HYP在UC治疗中的疗效.
研究的目的:
- 开发高酸载荷混合 (HYP-M) 以改善HYP的口服输送.
- 评估HYP-M的物理化学特性和稳定性.
- 评估HYP-M在性结肠炎模型中的疗效.
主要方法:
- 制备和描述HYP-M,包括颗粒大小,PDI,ZP和捕获效率.
- 在体外药物释放研究.
- 在体内药理动力学分析和反UC效应的评估.
主要成果:
- HYP-M 显示出有利的物理化学特性:粒子大小 (21.48 nm),PDI (0.178),ZP (-20.00 mV) 和高捕获效率 (89.59%).
- 试验室和体内研究显示,HYP释放显著增强,与自由HYP相比,口服生物可用性增加4.15倍.
- 与自由HYP相比,HYP-M在治疗UC方面表现出更高的治疗效率.
结论:
- HYP-M代表了一种有希望的纳米载体系统,用于增强HYP的口服生物可用性.
- 开发的HYP-M配方有效地改善了hyperoside的抗性结肠炎活性.
- 这种方法提供了一种新的策略,用于治疗性结肠炎使用hyperoside.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
209
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
209
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186


